Evidence map›Paper›PMID 37611527›Full record

Trial reportPsychoneuroendocrinology2023

Effects of estrogen and progesterone on neuroactive steroids and cytokines in patients with suicidality.

Jordan C Barone, Elizabeth Wenzel, Viraja Alluri, Daniel Moriarity, Graziano Pinna, Erin Walsh, David R Rubinow, A Leslie Morrow, Tory A Eisenlohr-Moul

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Psychoneuroendocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03720847 (Ovarian Hormone Withdrawal and Suicide Risk), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03720847 phase4completednot on this map

Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2016 to 2017Enrolled30ConditionsSuicidal IdeationArmsEstradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jordan C BaroneUniversity of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 60612, USA. Electronic address: jbarone2@uic.edu.
Elizabeth WenzelUniversity of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 60612, USA.
Viraja AlluriUniversity of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 60612, USA.
Daniel MoriarityUniversity of California, Los Angeles, Department of Psychiatry and Biobehavioral Sciences, 757 Westwood Plaza #4, Los Angeles, CA 90095, USA; Stanford University, Department of Genetics, 291 Campus Drive, Stanford, CA 94305, USA.
Graziano PinnaUniversity of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 60612, USA.
Erin WalshUniversity of North Carolina-Chapel Hill, Department of Psychiatry, 101 Manning Dr. #1, Chapel Hill, NC 27514, USA.
David R RubinowUniversity of North Carolina-Chapel Hill, Department of Psychiatry, 101 Manning Dr. #1, Chapel Hill, NC 27514, USA.
A Leslie MorrowUniversity of North Carolina-Chapel Hill, Department of Psychiatry, 101 Manning Dr. #1, Chapel Hill, NC 27514, USA.
Tory A Eisenlohr-MoulUniversity of Illinois at Chicago, Dept of Psychiatry, 912 S Wood St, Chicago, IL 60612, USA.
University of Illinois Chicago · USUniversity of North Carolina at Chapel Hill · USUniversity of California, Los Angeles · US

Funding

Training in the Neuroscience of Mental HealthT32MH067631 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RASENICK, MARK M. · 2004 to 2024
$4.8M
Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental ApproachRF1MH120843 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI EISENLOHR-MOUL, TORY ANNE · 2019 to 2019
$3.1M
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental ApproachR00MH109667 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI EISENLOHR-MOUL, TORY ANNE · 2018 to 2020
$747k
Testing a Social Safety Theory Perspective on Depression: An Intensive Longitudinal Immunopsychiatric Data ApproachF32MH130149 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIARITY, DANIEL P · 2022 to 2024
$210k
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental ApproachK99MH109667 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EISENLOHR-MOUL, TORY ANNE · 2016 to 2017
$164k
An RDoC Approach to Perinatal Affective Disorders: The Role of Neuroactive Steroids and Potential ThreatF31MH130077 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI WENZEL, ELIZABETH · 2022 to 2023
$85k
NIMH NIH HHS F31 MH130077NIMH NIH HHS F32 MH130149NIMH NIH HHS K99 MH109667NIMH NIH HHS R00 MH109667NIMH NIH HHS RF1 MH120843NIMH NIH HHS T32 MH067631
6 · The paper itself

Abstract

backgroundIn ovulating psychiatric patients experiencing suicidality, suicidal ideation (SI) often peaks perimenstrually. Our recent double-blind, placebo-controlled, crossover randomized clinical trial (RCT; NCT03720847) showed that perimenstrual administration of estradiol and progesterone (EP) can prevent this peak in SI and depressed mood. In this pre-registered follow-up analysis, we studied how the menstrual cycle and experimental manipulation affected two neurobiological systems associated with the menstrual cycle and suicide risk: GABAergic neuroactive steroids (NAS) and peripheral cytokines.

methodsIn 26 psychiatric outpatients with natural menstrual cycles and past-month SI, we analyzed serum samples from three blood draws (midluteal, perimenstrual, midfollicular) per experimental condition (EP vs placebo) timed to a luteinizing hormone-surge ovulation test. Using gas chromatography/mass spectrometry (GC/MS), we measured the progesterone (P4)-derived pregnane NAS (3α,5α)- 3-hydroxypregnan20-one (3α,5α-THP), (3α,5β)- 3-hydroxypregnan-20-one (3α,5β-THP), (3α,5α)- 3,21-dihydroxypregnan-20-one (3α,5α-THDOC), (3α,5α)- 3-hydroxyandrostan-17-one (3α,5α-A), the androstane NAS (3α,5β)- 3-hydroxyandrostan-17-one (3α,5β-A), (3α,5α,17β)-androstane-3,17-diol (3α,5α-A-diol), (3α,5β,17β)-androstane-3,17-diol (3α,5β-A-diol), and their precursor pregnenolone. High sensitivity multiplex assay kits quantified peripheral cytokines IL-1β, IL-6, and TNF-α.

resultsP4-derived NAS fluctuated in parallel with P4 and increased with exogenous perimenstrual administration of EP. Conversely, androstane NAS either did not fluctuate or fluctuated inversely from P4, and these NAS decreased with exogenous EP. Peripheral cytokines did not show cyclical patterns, but each significantly predicted SI, depressed mood, or anxiousness. Concomitant SSRI medication use predicted lower androstane NAS.

conclusionsWhile preliminary and exploratory, our findings provide critical descriptive context for future studies. Further, our work presents menstrual cycle-related patterns for ten frequently-studied biomarkers, allowing for improved quality of comparisons involving naturally-cycling populations in research.

Indexed as

NeurosteroidsSuicideAndrostane-3,17-diolAndrostanesCytokinesEstradiolEstrogensFemaleHumansProgesteroneSuicidal IdeationAndrostane-3,17-diolAndrostanesCytokinesEstradiolEstrogensNeurosteroidsProgesteroneClinical trialCytokinesMenstrual cycleNeuroactive steroidsPremenstrual mood disordersSuicidal ideation

Identifiers

PMID37611527
PMCPMC10543480
OpenAlexW4385892645

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.